Drugs / TORUDOKIMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03913260 | May → Sep 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03343587 | Nov 2017 → Nov 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03831191 | Feb 2019 → Feb 2020 | atopic eczema | Eli Lilly and Company | Terminated | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TORUDOKIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650487 ↗ |
| Known as | LY3375880 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03343587 ↗ |
| Action | Inhibit | “Interleukin-33 inhibitor” CHEMBL4650487 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650487 ↗ |
| Route | Intravenous | “administered IV” NCT03343587 ↗ |
| Target | IL33 | “Interleukin-33 inhibitor” CHEMBL4650487 ↗ |